gilead sanofi - Search News

News

Sanofi, Gilead Sciences and Kymera

Kymera Shrugs Off Sanofi Bust With Gilead Deal--But There Are Caveats

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers hope. Click for my GILD and KYMR update.

BioPharma Dive · 1d

Kymera adds Gilead as research partner, while advancing new candidate with Sanofi

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a new drug prospect, meanwhile.

pharmaphorum · 1d

Kymera signs $750m cancer deal with Gilead as Sanofi opts in

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular glue programme, as Sanofi buys into another.

Fierce Biotech2h

Gilead blames low RSV infection rates last season for scrapping 2 obeldesivir trials

Gilead has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two mid-stage trials of ...

Zacks Investment Research on MSN21h

KYMR Collaborates With GILD; Stock Down on Sanofi Deal Update

Kymera Therapeutics, Inc. KYMR has announced that partner Sanofi SNY will not advance the development of lead IRAK4 degrader ...

Fierce Pharma15h

GSK, Gilead, Novo Nordisk join other Big Pharmas in honoring 2025 LGBTQ+ Pride month

A Fierce Pharma Marketing review of the LinkedIn and Instagram pages of the 20 largest pharmas found that, as of Thursday, ...

Medscape2h

Does Elinzanetant Reduce VMS in Younger Patients With HR+ Breast Cancer?

Elinzanetant is the first neurokinin-targeted therapy to demonstrate efficacy in reducing vasomotor symptoms (VMS)” — ...

BioWorld12h

Pump manufacturers: Patches are the fix for low AID uptake

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with ...

Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies

Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results